title: Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination.
abstract: It is now well recognised that heparin possesses numerous anti-inflammatory properties in addition to its anticoagulant properties. Thus, the aim of this study was to investigate the effects of the low molecular weight heparin, enoxaparin (ENX), as an add-on therapy for a period of 12 weeks, to inhaled salmeterol/fluticasone propionate (SLM/FP) combination in patients with stable chronic obstructive pulmonary disease (COPD). Forty-six patients were randomised to receive 12 weeks of treatment in one of two treatment groups: (1) fixed combination of SLM 50 microg and FP 500 microg Diskus, one inhalation twice daily; or (2) as group 1 plus 20 mg ENX administered subcutaneously once daily for 12 weeks. Patients attended the clinic before and after 4, 8 and 12 weeks of treatment for evaluations of lung function, blood gas tensions, dyspnoea and supplemental salbutamol use. Thirty-six patients completed the 12-week treatment period, 20 from group 1 and 16 from group 2. A significant increase in forced expiratory volume in 1 s (FEV1) over baseline was observed after 12 weeks of treatment in group 1 (0.145 L, 95% CI: 0.994-1.406, p<0.01), whilst significant increases in FEV1 over baseline were observed in group 2 after 4, 8 and 12 weeks of treatment with a maximum increase at 12 weeks of 0.244 L (95% CI: 1.175-1.596, p<0.01). Both treatment groups experienced similar improvements in blood gas tensions, dyspnoea and supplemental salbutamol use. Our results suggest that addition of ENX to conventional therapy of COPD may provide additional clinical benefit and must be further investigated as a treatment for COPD.
authors.affiliation: Sackler Institute of Pulmonary Pharmacology, King's College London, Guy's Campus, London, UK.
authors.forename: Rachel A
authors.initials: RA
authors.lastname: Brown
authors.forename: Luigi
authors.initials: L
authors.lastname: Allegra
authors.forename: Maria G
authors.initials: MG
authors.lastname: Matera
authors.forename: Clive P
authors.initials: CP
authors.lastname: Page
authors.forename: Mario
authors.initials: M
authors.lastname: Cazzola
mesh_terms: D000368:Aged; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D001784:Blood Gas Analysis; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000188:drug therapy / Q000503:physiopathology; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D000068298:Fluticasone; D006801:Humans; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D012129:Respiratory Function Tests; D000068299:Salmeterol Xinafoate; D014797:Vital Capacity
chemical_list: D000730:Androstadienes; D000925:Anticoagulants; D001993:Bronchodilator Agents; D017984:Enoxaparin; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol